4.4 Article

Higher expression of circulating miR-182 as a novel biomarker for breast cancer

Journal

ONCOLOGY LETTERS
Volume 6, Issue 6, Pages 1681-1686

Publisher

SPANDIDOS PUBL LTD
DOI: 10.3892/ol.2013.1593

Keywords

miR-182; circulating miRNAs; breast cancer; diagnosis; gene expression

Categories

Funding

  1. National Natural Science Foundation [31371321, 81141114, 81200601]
  2. Foundation of Shandong Educational Committee of China [J10LC60, J11LC01]
  3. [NCET-10-0919]

Ask authors/readers for more resources

MicroRNAs (miRNAs), present in the serum in a stable and reproducible manner, may be used as biomarkers for various diseases. Few studies have previously investigated circulating miRNAs in the peripheral blood of breast cancer (BC) patients. To identify the role of serum miR-182 levels in BC, the present study detected miR-182 levels in the serum of 46 BC patients and 58 controls, by quantitative PCR. The results showed that the serum miR-182 levels in BC patients were significantly higher compared with the serum of healthy controls (P<0.01). The miR-182 was also overexpressed in the BC tissues compared with the para-carcinoma tissues. Furthermore, the serum levels of miR-182 in the estrogen receptor (ER)-positive patients were considerably lower compared with those in the ER-negative patients. The serum levels of miR-182 in the progesterone receptor (PR)-positive patients were also found to be lower compared with those in the PR-negative patients. The current study highlights results consistent with miR-182 as a novel and valuable biomarker for the diagnosis of BC.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available